Three independent discounted-cash-flow-style models value Esperion Therapeutics, Inc. every trading day. 0 of 3 currently price ESPR above its market price.
| Free Cash Flow model | $-155.65 |
| Excess Profit model | $-191.70 |
| Residual Earnings model | $-0.18 |
| Dividend Discount model | — |
| Piotroski F-Score | 3 / 9 |
| Return on invested capital | +28.8% |
| Net debt / EBITDA | 7.7× |
| Gross margin | +100.0% |
| Revenue CAGR | +74.8% |
| Cash conversion | — |
| Dividend yield | — |
| Buyback yield | -11.0% |
These are StockKitty's default assumptions. In the app, the models recompute live as you adjust growth, discount rates, and margins — and the AI explains the bull case, bear case, and quality picture.
Open ESPR in StockKitty